KINAXO and Bayer Vital GmbH Collaborate in Phosphoproteomics Biomarker Identification
News Oct 29, 2009
KINAXO Biotechnologies GmbH and Bayer Vital GmbH announced that they will enter into collaboration. KINAXO will apply its quantitative phosphoproteomics technology PhosphoScout® for the identification of novel biomarkers in a clinical trial conducted by Bayer Vital.
KINAXO’s phosphoproteomics platform allows annotation and quantification of regulated phosphorylation sites. Since the majority of targeted compounds used as anti-cancer drugs influence cellular signal transduction pathways, analysis of phosphorylation patterns in relation to drug administration reveals a compound’s molecular mode of action.
Characteristic phosphorylation sites predicting response to treatment, resistance mechanism or synergistic effects can hereby be identified as biomarkers which allow for personalized treatment plans.
Accompanying a clinical trial for the multi-kinase inhibitor Nexavar® in Acute Myeloid Leukemia (AML), KINAXO will apply its phosphoproteomics technology to reveal the drug’s influence on cellular phosphorylation patterns and to search for novel predictive biomarkers.
Nexavar® is already approved for the treatment of hepatocellular (HCC) and renal cell carcinoma (RCC) and shows promising effects in several other indications, amongst them AML, the most common type of leukemia in adults. Despite considerable efforts over the last decades, therapeutic outcome in AML therapy has improved only modestly and remains dismal, with a high number of patients being non-responsive to standard treatment or recurrent. Application of KINAXO’s phosphoproteomics technology could thus turn out to be a valuable tool to discover predictive biomarkers that foretell therapeutic outcome in patients.
Furthermore, quantitative phosphoproteomics will be applied to investigate the molecular efficiency of potential combination therapies in which Nexavar® will be administered together with other targeted drugs to effectively fight cancer. In turn, individualized therapeutic strategies could then improve overall treatment outcome for malignant diseases, such as AML.
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE
Researchers Discover Mutation That Appears to Protect Against Multiple Aspects of Biological AgingNews
The first genetic mutation that appears to protect against multiple aspects of biological aging in humans has been discovered in an extended family of Old Order Amish living in the vicinity of Berne, Indiana, report Northwestern Medicine scientists.READ MORE
Researchers Find a Way to Separate Side Effects of Opioid Drugs Reducing RiskNews
Scientists have discovered a way to separate these two effects -- pain relief and breathing, opening a window of opportunity to make effective pain medications without the risk of respiratory failure.READ MORE